FDA approves first treatment for anemia in beta thalassemia patients

FDA approved on Friday Reblozyl luspatercept-aamt from Celgene and Acceleron as the first treatment for anemia in β thalassemia patients who require red blood cell transfusions. The erythroid maturation agent will be available to patients

Read the full 351 word article

User Sign In